Amanat Acquisition Corp to Merge with Corxel Pharmaceuticals

Amanat Acquisition Corp. and Corxel Pharmaceuticals have signed a definitive business combination agreement under which Corxel US will become a wholly owned subsidiary of the combined public company. The transaction is expected to generate approximately $377 million in gross proceeds, assuming no redemptions, to support global Phase 3 development of Corxel’s obesity candidate CX11. Both boards have approved the deal, which is expected to close in the first half of 2027 pending shareholder and regulatory approvals; the combined company will adopt a new name and ticker to be announced before closing.